Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04VBF
|
|||
| Former ID |
DIB015670
|
|||
| Drug Name |
JNJ-38518168
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [2] | ||
| Company |
Janssen research & development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H32N6
|
|||
| Canonical SMILES |
CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C
|
|||
| InChI |
1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
|
|||
| InChIKey |
FCRFVPZAXGJLPW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 952494-46-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H4 receptor (H4R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCR ligand binding | |||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02295865) A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis. U.S. National Institutes of Health. | |||
| REF 3 | The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.